Citations

Clear

7732 citation(s) found for "Ma, Daniel".

An X-band hybrid MIC feedforward amplifier for low residual noise operation
Соколов, В. А. , Kruchowski, James, Vickberg, M., Buhrow, Benjamin , Schuster, S.E., Bublitz, J., Gilbert, Barry K., Daniel, Erik S.

Mayo Clinic

IEEE MTT-S International Microwave Symposium Digest, 2005. | October 11, 2006 | Volume: No volume available | Issue: No issue available | Pages: 2039-2042

10.1109/mwsym.2005.1517146 Get It

Microsatellite Instability in Cancer of the Proximal Colon
Thibodeau, Stephen N. , Bren, Gary D., Schaid, Daniel J.

Mayo Clinic

Science | October 5, 2006 | Volume: 260 | Issue: 5109 | Pages: 816-819

10.1126/science.8484122 | PMID 8484122 Get It

Colorectal tumor DNA was examined for somatic instability at (CA) n repeats on human chromosomes 5q, 15q, 17p, and 18q. Differences between tumor and normal DNA were detected in 25 of the 90 (28 percent) tumors examined. This instability appeared as either a substantial change in repeat length (often heterogeneous in nature) or a minor change (typically two base pairs). Microsatellite instability was significantly correlated with the tumor's location in the proximal colon ( P = 0.003), with increased patient survival ( P = 0.02), and, inversely, with loss of heterozygosity for chromosomes 5q, 17p, and 18q. These data suggest that some colorectal cancers may arise through a mechanism that does not necessarily involve loss of heterozygosity.
Sam Wieand, PhD
Haller, Daniel G. , Costantino, Joseph P., O’Connell, Michael J. , Sargent, Daniel J. , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | September 28, 2006 | Volume: 24 | Issue: 28 | Pages: 4523-4525

10.1200/jco.2006.08.6587 Get It

Aberrant Nuclear Accumulation of Glycogen Synthase Kinase-3β in Human Pancreatic Cancer: Association with Kinase Activity and Tumor Dedifferentiation
Ougolkov, Andrei V., Fernández-Zapico, Martín E. , Smyrk, Thomas C. , Chari, Suresh T. , Billadeau, Daniel D. , Ugolkov, Andrey , Bilim, Vladimir N. , Chari, Suresh T

Mayo Clinic

Clinical Cancer Research | September 1, 2006 | Volume: 12 | Issue: 17 | Pages: 5074-5081

10.1158/1078-0432.ccr-06-0196 | PMID 16951223 Get It

Abstract Purpose: We have shown recently that glycogen synthase kinase-3 (GSK-3) β regulates nuclear factor-κB (NF-κB)–mediated pancreatic cancer cell survival and proliferation in vitro. Our objective was to determine the localization of GSK-3β in pancreatic cancer cells and assess the antitumor effect of GSK-3 inhibition in vivo to improve our understanding of the mechanism by which GSK-3β affects NF-κB activity in pancreatic cancer. Experimental Design: Immunohistochemistry and cytosolic/nuclear fractionation were done to determine the localization of GSK-3β in human pancreatic tumors. We studied the effect of GSK-3 inhibition on tumor growth, cancer cell proliferation, and survival in established CAPAN2 tumor xenografts using a tumor regrowth delay assay, Western blotting, bromodeoxyuridine incorporation, and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling. Results: We found nuclear accumulation of GSK-3β in pancreatic cancer cell lines and in 62 of 122 (51%) human pancreatic adenocarcinomas. GSK-3β nuclear accumulation is significantly correlated with human pancreatic cancer dedifferentiation. We have found that active GSK-3β can accumulate in the nucleus of pancreatic cancer cells and that inhibition of GSK-3 kinase activity represses its nuclear accumulation via proteasomal degradation within the nucleus. Lastly, we have found that inhibition of GSK-3 arrests pancreatic tumor growth in vivo and decreases NF-κB-mediated pancreatic cancer cell survival and proliferation in established tumor xenografts. Conclusions: Our results show the antitumor effect of GSK-3 inhibition in vivo, identify GSK-3β nuclear accumulation as a hallmark of poorly differentiated pancreatic adenocarcinoma, and provide new insight into the mechanism by which GSK-3β regulates NF-κB activity in pancreatic cancer.
Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer
Goldberg, Richard M. , Tabah-Fisch, Isabelle, Bleiberg, Harry, Gramont, Aimery de , Tournigand, Christophe , André, Thierry , Rothenberg, Mace L., Green, Erin , Sargent, Daniel J. , Sargent, Daniel J , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | August 31, 2006 | Volume: 24 | Issue: 25 | Pages: 4085-4091

10.1200/jco.2006.06.9039 | PMID 16943526 Get It

Purpose Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer. This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than and at least 70 years. Patients and Methods This retrospective analysis included 3,742 colorectal cancer patients (614 age ≥ 70) from four clinical trials testing FOLFOX4 in the adjuvant, first-, and second-line settings. End points included grade ≥ 3 adverse events, response rate (in advanced disease), progression or relapse-free survival, dose-intensity, and overall survival in the studies with mature survival data. Results Grade ≥ 3 hematologic toxicity (neutropenia [43% v 49%; P = .04] and thrombocytopenia [2% v 5%; P = .04]) were significantly higher in older patients. Older age was not associated with increased rates of severe neurologic adverse events, diarrhea, nausea/vomiting, infection, overall incidence of grade ≥ 3 toxicity (63% v 67%; P = .15), or 60-day mortality (1.1% v 2.3%; P = .20). The relative benefit of FOLFOX4 versus control did not differ by age for response rate, progression or recurrence free-survival (hazard ratio, 0.70 for FOLFOX4 v control for age < 70, 0.65 for age ≥ 70; P = .42), or overall survival (hazard ratio, 0.77 age < 70, 0.82 age ≥ 70; P = .79). Dose-intensity did not differ by age at cycles 1, 3, 6, or 12. Conclusion FOLFOX4 maintains its efficacy and safety ratio in selected elderly patients with colorectal cancer. Its judicious use should be considered without regard to patient age, although scant data are available among patients older than 80 years.
IC–P–024: MRI, MRS and clinical correlates in posterior cortical atrophy and typical Alzheimer's disease
Whitwell, Jennifer L. , Drubach, Daniel A., Tang‐Wai, David F. , Petersen, Ronald C. , Josephs, Keith A. , Jack, Clifford R. , Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_21 | Pages: No page available

10.1016/j.jalz.2006.05.2229 Get It

P4–412: The use of a rehabilitation inventory and interdisciplinary approach in the treatment of patients with cortico basal degeneration syndrome
Drubach, Daniel A.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_21 | Pages: No page available

10.1016/j.jalz.2006.05.2154 Get It

P4–196: The capacity of persons with very mild to moderate AD to provide informed consent to enroll in a clinical trial
Karlawish, Jason , vanDyck, Christopher, Marson, Daniel , Kim, Scott Y. H. , Knopman, David S. , James, Bryan D.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_19 | Pages: No page available

10.1016/j.jalz.2006.05.1935 Get It

P4–161: The Lewy body variant of posterior cortical atrophy
Josephs, Keith A. , Whitwell, Jennifer L. , Tang‐Wai, David F. , Parisi, Joseph E., Drubach, Daniel A., Petersen, Ronald C. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_18 | Pages: No page available

10.1016/j.jalz.2006.05.1900 Get It

P2–348: MRI, MRS and clinical correlates in posterior cortical atrophy and typical Alzheimer's disease
Whitwell, Jennifer L., Drubach, Daniel A., Tang‐Wai, David F. , Petersen, Ronald C. , Josephs, Keith A. , Whitwell, Jennifer , Jack, Clifford R. , Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_11 | Pages: No page available

10.1016/j.jalz.2006.05.1188 Get It